Bio-Gene Technology has raised A$3.21 million to complete critical safety studies for its novel insecticide Flavocide and ramp up production of its natural insecticide Qcide, advancing its path to commercialisation in multiple global markets.
- A$2.71m placement plus A$0.5m underwritten SPP
- Funds to complete Flavocide regulatory studies for Australian approval
- Increased Qcide production to meet partner demand
- Options attached to raise subject to shareholder approval
- Commercial partnerships and US DoD grants underpin growth
Capital Raise Targets Regulatory Milestone and Production Scale-Up
Bio-Gene Technology Limited (ASX:BGT) has secured approximately A$3.21 million through a two-tranche placement and a partially underwritten Share Purchase Plan (SPP), aiming to fund the completion of pivotal safety studies for its flagship insecticide Flavocide and to boost production of Qcide, its companion natural insecticide. The $2.71 million placement was priced at 2.5 cents per share, representing a discount of nearly 14% to the last close, with one free attaching option for every two shares issued, exercisable at 3.5 cents and expiring in October 2027, pending shareholder approval.
This capital injection comes as Bio-Gene accelerates its regulatory submission timeline for Flavocide, targeting the Australian Pesticides and Veterinary Medicines Authority (APVMA) dossier lodgement by March 2027, a critical step toward commercialisation. The funding will also underpin product development activities supporting its expanding commercial partnerships across public health, agriculture, and consumer markets.
Flavocide and Qcide: Natural Insecticides with Global Reach
Flavocide and Qcide are derived from a unique eucalypt cultivar native to northern Australia, offering novel modes of action against pests resistant to conventional insecticides. Flavocide, synthesised via a proprietary process, has demonstrated rapid knockdown and 100% mortality against mosquito species like Aedes aegypti and Culex quinquefasciatus in laboratory tests, positioning it for applications in public health vector control and crop protection.
Qcide, a 100% natural oil, recently completed its 15th harvest in Queensland and is OMRI-listed for organic use in the US. Bio-Gene’s strategic partnerships include Clarke Mosquito in the US, Evergreen Garden Care across Europe and Australasia, and a collaboration with Sumitomo Corporation and Nakashima Trading to launch Qcide in Japan’s $1 billion household pest market by late 2026. These partnerships underscore the commercial validation of Bio-Gene’s technology and its multi-territory ambitions.
Backing from US Department of Defense Grants
Bio-Gene’s projects have attracted approximately A$3 million in US Department of Defense (DoD) grants under the Deployed Warfighter Protection program, aimed at developing insecticide solutions to protect military personnel from disease vectors. These grants support a wearable emanator device containing Flavocide and a sprayable Qcide formulation targeting bed bugs and crawling insects, with collaborations involving the Walter Reed Army Institute of Research and other US military research bodies. This endorsement not only validates the efficacy of Bio-Gene’s products but also opens pathways to dual-use military and civilian markets.
The company’s recent progress includes pilot-scale production of Flavocide at Rallis India Ltd and ongoing regulatory-enabling toxicology studies, with multiple OECD-compliant studies underway or planned. This regulatory momentum is critical given the global insecticide market’s scale, estimated at US$44 billion across crop protection, public health, consumer, and animal health segments, with Bio-Gene targeting all four.
Shareholder Approval and Investor Participation
The placement’s second tranche, raising approximately A$0.8 million, and the issuance of attaching options are conditional on shareholder approval at an extraordinary general meeting scheduled for around 31 July 2026. The SPP offers eligible Australian shareholders the chance to acquire up to $15,000 in shares on the same terms, underwritten to a minimum of $500,000. This structure aims to broaden shareholder participation while ensuring the company’s capital requirements are met to sustain its regulatory and commercialisation activities.
Bio-Gene’s Managing Director Tim Grogan highlighted that the funds would enable the company to “continue to build momentum and accelerate our plans to commercialise both Flavocide and Qcide,” reflecting the strategic importance of these milestones for the company’s growth trajectory.
With a market capitalisation near A$8.8 million and cash reserves of just A$0.67 million as of March 2026, this capital raise is timely to maintain operational momentum and meet upcoming regulatory deadlines. The company’s experienced board and management team, boasting decades of expertise in agriculture, product development, and commercialisation, are poised to navigate this critical phase.
Bio-Gene’s regulatory and commercial progress has been tracked closely, with recent updates showing steady advancement of Flavocide toxicology studies and strategic partnerships for Qcide’s Japan launch, as detailed in the company’s Flavocide registration and Japan deal progress and Sumitomo and Nakashima Japan launch plans. The US DoD grants and organic certification further reinforce the company’s positioning in a competitive biological insecticide market US DoD grants and OMRI certification.
Bottom Line?
Bio-Gene’s latest capital raise is a vital step to secure regulatory approval and scale production, but shareholder backing of the second tranche and option issuance will be key to sustaining this momentum.
Questions in the middle?
- Will Bio-Gene meet its March 2027 target for Flavocide’s APVMA submission without delay?
- How quickly can Qcide production scale to satisfy demand from new commercial partners, especially in Japan?
- What impact will shareholder approval outcomes have on Bio-Gene’s near-term funding and operational plans?